CASI Pharmaceuticals Inc Total Liabilities
CASI Pharmaceuticals Inc total liabilities. Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has total liabilities worth $53.05 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are CASI Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CASI Pharmaceuticals Inc (1994–2024)
Total liabilities of CASI Pharmaceuticals Inc from 1994 to 2024. This chart illustrates how CASI Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CASI Pharmaceuticals Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
CASI Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henderson High Income Trust
LSE:HHI
|
UK | GBX67.03 Million |
|
Fidelity Asian Values
LSE:FAS
|
UK | GBX6.54 Million |
|
Invibes Advertising NV
PA:ALINV
|
France | €9.63 Million |
|
AKTIENBRAU.KAUFBEUR
MU:ABK
|
Germany | €5.77 Million |
|
Sego Resources Inc
V:SGZ
|
Canada | CA$470.19K |
|
Alliance Pharma plc
LSE:APH
|
UK | GBX161.50 Million |
|
Taiton Resources Ltd
AU:T88
|
Australia | AU$279.52K |
|
Nickel North Exploration Corp
V:NNX
|
Canada | CA$2.75 Million |
Liability Composition Analysis (1994–2024)
This chart breaks down CASI Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CASI Pharmaceuticals Inc (CASI) total assets.
Liquidity & Leverage Metrics
CASI Pharmaceuticals Inc Total Liabilities Ratios Explained
CASI Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CASI Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual total liabilities of CASI Pharmaceuticals Inc from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $51.82 Million | +1.41% |
| 2023-12-31 | $51.10 Million | +74.40% |
| 2022-12-31 | $29.30 Million | -3.42% |
| 2021-12-31 | $30.34 Million | +25.57% |
| 2020-12-31 | $24.16 Million | +169.47% |
| 2019-12-31 | $8.97 Million | +127.13% |
| 2018-12-31 | $3.95 Million | -39.83% |
| 2017-12-31 | $6.56 Million | -5.31% |
| 2016-12-31 | $6.93 Million | -41.84% |
| 2015-12-31 | $11.91 Million | +1.55% |
| 2014-12-31 | $11.73 Million | +1975.81% |
| 2013-12-31 | $565.17K | -23.91% |
| 2012-12-31 | $742.75K | +5.49% |
| 2011-12-31 | $704.09K | -73.96% |
| 2010-12-31 | $2.70 Million | -77.46% |
| 2009-12-31 | $11.99 Million | -47.86% |
| 2008-12-31 | $23.00 Million | -11.93% |
| 2007-12-31 | $26.12 Million | +198.88% |
| 2006-12-31 | $8.74 Million | +24.03% |
| 2005-12-31 | $7.05 Million | +91.34% |
| 2004-12-31 | $3.68 Million | -30.23% |
| 2003-12-31 | $5.28 Million | -69.49% |
| 2002-12-31 | $17.30 Million | -24.81% |
| 2001-12-31 | $23.01 Million | +86.24% |
| 2000-12-31 | $12.35 Million | +26.05% |
| 1999-12-31 | $9.80 Million | +53.13% |
| 1998-12-31 | $6.40 Million | +12.28% |
| 1997-12-31 | $5.70 Million | -10.94% |
| 1996-12-31 | $6.40 Million | -1.54% |
| 1995-12-31 | $6.50 Million | +983.33% |
| 1994-12-31 | $600.00K | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more